Facility Overview

Medicago operates a 14,000-square-foot production facility located in the “Parc Technologique du Québec Métropolitain” in Québec City, Québec. This facility includes a 10,000 sq. ft. of Biosafety Level 2 greenhouse spaces for plant growth, as well as 3,000 sq. ft. of cGMP manufacturing sites for plant manipulation, product recovery and purification.

In January 2010, Medicago completed the expansion of its current cGMP manufacturing facility. The expansion has provided additional space to produce Phase II clinical grade material. The facility expansion includes the addition of approximately 2,500 sq. ft., of expanded purification and production capacity to support increased cGMP production. Medicago expects to produce the preclinical and clinical lots required for the development of its influenza vaccines from its existing facility. The Company plans to invest $1.9 million in 2010 to expand its manufacturing activities and provide additional space to produce clinical-grade material for phase II human clinical trials.